Access to Innovative Treatments Act of 2026
Reps. Barragan and Joyce Introduce Bill to Challenge Medicare Drug Coverage Denials
This bill is currently in the early stages of the legislative process. It has been sent to two House committees for review and is not yet scheduled for a vote. The bill is considered active as it waits for further action from these committees.
Legislative Progress
The bill has support from both parties, which helps its chances, but changes to Medicare rules often face long delays and heavy debate in committee.
Key Points
Impact Analysis
Personal Impact
Programs
Social Security Disability Insurance (SSDI) recipients who qualify for Medicare after a waiting period would benefit indirectly from this bill. Since they rely on Medicare for drug coverage, the new review process for coverage denials could help them access FDA-approved treatments that Medicare has restricted.
Disabilities
Milestones
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
Access to Innovative Treatments Act of 2026
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.